{
    "clinical_study": {
        "@rank": "3331", 
        "arm_group": {
            "arm_group_label": "tacrolimus-cyclosporine A", 
            "arm_group_type": "Experimental", 
            "description": "conversion of immunosuppression from tacrolimus to cyclosporine A in hepatitis C-positive renal transplant recipients"
        }, 
        "brief_summary": {
            "textblock": "The aim of the present trial is to evaluate whether the conversion of immunosuppression from\n      tacrolimus to cyclosporine A induces changes in (i) hepatitis C-virus load, (ii) parameters\n      of hepatic function and (iii) parameters of glucose tolerance in hepatitis C-positive renal\n      transplant recipients."
        }, 
        "brief_title": "Hepatitis C in Renal Transplant Recipients", 
        "condition": [
            "Chronic Hepatitis C-virus Infection", 
            "Renal Transplantation"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Chronic", 
                "Hepatitis C", 
                "Virus Diseases", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  written informed consent\n\n          -  prior renal transplantation\n\n          -  current tacrolimus-based immunosuppressive regimen\n\n          -  hepatitis C-infection\n\n          -  age 18-70 years\n\n        Exclusion Criteria:\n\n          -  current hemodialysis or peritoneal dialysis\n\n          -  pregnancy or breastfeeding\n\n          -  known contraindication for cyclosporine A-treatment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 1, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02108301", 
            "org_study_id": "EK477/2011"
        }, 
        "intervention": {
            "arm_group_label": "tacrolimus-cyclosporine A", 
            "description": "conversion of immunosuppression from tacrolimus to cyclosporine A in hepatitis C-positive renal transplant recipients", 
            "intervention_name": "tacrolimus-cyclosporine A", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Cyclosporins", 
                "Cyclosporine", 
                "Tacrolimus"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "chronic hepatitis C-virus infection", 
            "renal transplantation", 
            "glucose tolerance", 
            "immunosuppression"
        ], 
        "lastchanged_date": "April 10, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Vienna", 
                    "country": "Austria", 
                    "zip": "1090"
                }, 
                "name": "Medical University of Vienna, Department of Internal Medicine III, Division of Nephrology and Dialysis"
            }
        }, 
        "location_countries": {
            "country": "Austria"
        }, 
        "number_of_arms": "1", 
        "official_title": "Hepatitis C in Renal Transplant Recipients - Safety and Efficacy of a Conversion of Immunosuppression to High-dose Cyclosporine A and Its Impact on Hepatitis C Virus-replication, Parameters of Liver Function and Glucose Tolerance. An Open Label Trial.", 
        "other_outcome": [
            {
                "measure": "serum creatinine levels", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "serum glutamic-pyruvic transaminase concentrations", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }
        ], 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "Austria: Ethikkommission", 
                "Austria: Agency for Health and Food Safety"
            ]
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "change in Hepatitis C-virus load at 12 weeks", 
            "safety_issue": "No", 
            "time_frame": "one day before and 4, 8 and 12 weeks after the conversion"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02108301"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Medical University of Vienna", 
            "investigator_full_name": "Prof. Dr. Alice Schmidt", 
            "investigator_title": "MD", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "change in oral glucose insulin sensitivity (OGIS) index at 12 weeks", 
                "safety_issue": "No", 
                "time_frame": "one day before and 12 weeks after the conversion"
            }, 
            {
                "measure": "change in serum hepcidin levels at 12 weeks", 
                "safety_issue": "No", 
                "time_frame": "one day before and 12 weeks after the conversion"
            }
        ], 
        "source": "Medical University of Vienna", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Prof. Dr. Alice Schmidt", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2011", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}